Lung cancer after neoadjuvant therapy

Creating Lung cancer after neoadjuvant therapy is assessed using a consensus protocol.

Major pathologic response

$V={{T} \over {B}}\times 100\%$

Where:

V = percent viable tumour.

T = tumour area.

B = tumour bed area.

Major pathologic response is defined as: V <=10%.

Sign out

At cut-up the tumour bed was estimated at 5.0 cm. The residual cancer's size is estimated as 1.5 cm (based on a linear measurement of the tumour on slide D15-D16).  

The estimated viable tumour was assessed in slides D14-D17 and was determined to be: 30%. The estimated viable tumour EXCEEDS the cut-off value (<=10%); thus, the specimen is NEGATIVE for a major pathologic response.[1]  

1. J Thorac Oncol. 2020 May;15(5):709-740. doi: 10.1016/j.jtho.2020.01.005 

At cut-off value for major pathology response

The estimated viable tumour was assessed in slides C10-C13 and was determined to be: 10%. The estimated viable tumour is at the cut-off (<=10%) for major pathologic response.[1]  Additional sections of the tumour bed are negative; thus, a major pathologic response is favoured.

1. J Thorac Oncol. 2020 May;15(5):709-740. doi: 10.1016/j.jtho.2020.01.005 

See also

• Neoadjuvant therapy.